palifermin
Sign in to saveAlso known as FGF-7, HBGF-7, Fibroblast growth factor- 7, KGF, Keratinocyte growth factor precursor
Palifermin (trade name Kepivance, marketed by Biovitrum) is a truncated human recombinant keratinocyte growth factor (KGF) produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2005
- Admin. routes
- parenteral
- Indications
- leukemia, HIV infection, Hodgkins lymphoma, myelodysplastic syndrome
via ChEMBL · EBI
Wikidata facts
Show 1 more fact
- defined daily dose
- 4.2
Sources (3)
via Wikidata · CC0
~7 min read
Article
15 sectionsContents
- Therapeutic use(s)
- Drug target and mechanism of action
- Side effects
- Administration
- Drug interactions
- Pre-clinical trials
- Toxicology studies
- Clinical trials
- Phase I
- Phase II
- Phase III
- Costs
- Annual sales
- References
- External links
Palifermin (trade name Kepivance, marketed by Biovitrum) is a truncated human recombinant keratinocyte growth factor (KGF) produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract.
==Therapeutic use(s)== When patients with blood cancers (leukemia and lymphoma) receive high dose chemotherapy and radiation therapy to undergo bone marrow transplantation, they usually get severe oral mucositis. Palifermin reduces the incidence and duration of severe oral mucositis by protecting those cells and stimulating the growth of new epithelial cells to build up the mucosal barrier.
Available in 11 languages
via Wikidata sitelinks · CC0